CAS 115103-85-0

Propanoic acid, 3-[[[3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl][[3-(dimethylamino)-3-oxopropyl]thio]methyl]thio]-, sodium salt, (E)- (9CI)

CAS : 115103-85-0

Formule : C₂₆H₂₆ClN₂NaO₃S₂

Degré de pureté : 95%

Couleur et forme : Solid

Masse moléculaire : 537.0690

Ref: IN-DA000GAW

MK-571 sodium

CAS : 115103-85-0

MK-571 sodium

Degré de pureté : ≥95%

Masse moléculaire : 537.07g/mol

Ref: 54-BUP10478

MK-571 sodium salt

CAS : 115103-85-0

Formule : C₂₆H₂₆ClN₂O₃S₂·Na

Degré de pureté : ≥ 97%

Couleur et forme : White to light yellow or beige solid

Masse moléculaire : 537.1

Ref: 7W-GL9206

MK-571 sodium

CAS : 115103-85-0

MK-571 sodium, a CysLT1 antagonist and MRP2 inhibitor, obstructs drug efflux and hampers enterocyte phase-2 conjugation of flavonoids.

Formule : C₂₆H₂₇ClN₂O₃S₂·Na

Degré de pureté : 97.86% - 99.58%

Couleur et forme : Solid

Masse moléculaire : 537.07

Ref: TM-T3148

MK-571 sodium

CAS : 115103-85-0

MK-571 is a drug that belongs to the class of ATP-binding cassette transporters. MK-571 has been shown to inhibit multidrug efflux pumps, such as P-glycoprotein (P-gp), and to bind DNA. The optimum concentration of this drug is 0.1 μM, which can be achieved by using MK-571 with nonsteroidal anti-inflammatory drugs (NSAIDs). This agent has been shown to have a protective effect on the myocardium following a myocardial infarct and may also have an inhibitory effect on leukotriene synthesis in bowel disease. MK-571 has also been shown to inhibit polymerase chain reactions and may act as an inhibitor of apical secretions in the gastrointestinal tract.

Formule : C₂₆H₂₇ClN₂NaO₃S₂

Degré de pureté : Min. 95%

Masse moléculaire : 538.08 g/mol

Ref: 3D-QEA10385